{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.8","upperLimit":"57.9","value":"40.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"title":"PD-L1 < 1%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.9","upperLimit":"62.5","value":"49.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"title":"PD-L1 >= 1%"}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"}],"units":"Participants"}],"description":"ORR was defined as percentage of participants with BOR of CR or PR. Expression level of PD-L1 was assessed in tumor biopsy samples by immunohistochemistry (IHC). -CR: All target and nontarget lesion(s) no longer visible, maintained for at least 4 weeks and no new lesions. -PR: Decrease of at least 50% in the sum the products of perpendicular longest dimensions of target lesion(s), maintained for at least 4 weeks and no new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received cemiplimab 350 mg IV Q3W during each 9-week treatment cycle, for up to 108 weeks (12 cycles).","id":"OG000","title":"Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W"}],"paramType":"NUMBER","populationDescription":"The biomarker analysis set (BAS) included all participants in the FAS who had samples evaluable for PD-L1 assay. Here, 'Overall number of participants analyzed' is the number of participants who are evaluable for this outcome measure and \"Number analyzed\" is the number of participants in each row category. Only Group 6 was planned for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to 108 weeks","title":"ORR by Independent Central Review for Participants With Evaluable PD-L1 Assays","type":"SECONDARY","unitOfMeasure":"percentage of participants"}